03 July 2024 : Clinical Research
Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma
Jie Wang1ABCDEFG*, Ming Yang2CD, Sheng Chen2CEF, Hongbo Zhu1AB, Zhirong Zhang1CDDOI: 10.12659/MSM.943551
Med Sci Monit 2024; 30:e943551
Table 2 Correlation between CST1 and the clinicopathological factors.
Characters | CST1 | P* | Effect size | |
---|---|---|---|---|
Low | High | |||
Gender | ||||
Male | 40 | 14 | 0.688 | 0.044 |
Female | 21 | 9 | ||
Age | ||||
≤60 | 46 | 16 | 0.589 | 0.059 |
>60 | 15 | 7 | ||
Tumor diameter (cm) | ||||
≤5 | 26 | 6 | 0.164 | 0.152 |
>5 | 35 | 17 | ||
Macroscopic type | ||||
Ulcerative | 39 | 13 | 0.184 | |
Polypoid | 7 | 6 | 0.242 | |
Others | 15 | 4 | ||
Lesion number | ||||
Single | 50 | 18 | 0.700 | 0.042 |
Multiple | 11 | 5 | ||
Site | ||||
Stomach | 35 | 12 | 0.668 | 0.047 |
Intestine | 26 | 11 | ||
Chemotherapy | ||||
No | 31 | 9 | 0.477 | 0.104 |
Yes | 30 | 14 | ||
Serum LDH | ||||
Normal | 43 | 11 | 0.053 | 0.211 |
High | 18 | 12 | ||
PS | ||||
<2 | 55 | 18 | 0.149 | 0.157 |
2–4 | 6 | 5 | ||
Luanguo stage | ||||
I–II1 | 49 | 16 | 0.293 | 0.115 |
II2–IV | 12 | 7 | ||
IPI | ||||
<3 | 59 | 18 | 0.007 | 0.298 |
3–5 | 2 | 5 | ||
* chi-square test. LDH – lactate dehydrogenase; PS – performence status; IPI – International Prognostic Index; CST1 – Cystatin SN. |